

Ad Scientiam and Kyowa Kirin Join Forces to Pioneer Digital Biomarkers for XLH, a Rare Bone Disease

Paris, May 21, 2024 – Ad Scientiam, a leading Medtech company specializing in digital biomarkers, and Kyowa Kirin, a Japan-based global specialty pharmaceutical company, are proud to announce a strategic partnership aimed at driving innovation in the realm of digital biomarkers for X-linked hypophosphatemia (XLH), the most prevalent form of hereditary hypophosphatemia.

XLH is a rare and debilitating genetic disorder caused by various variants in the PHEX gene. It is characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth, presenting a substantial burden on patients' quality of life. Musculoskeletal symptoms such as fractures, pain, joint stiffness, osteoarthritis, enthesopathy, and muscle weakness are prominent features of the disease.

The collaboration between Ad Scientiam and Kyowa Kirin aims to develop and validate novel digital biomarkers tailored to the specific needs of patients with XLH. Leveraging Ad Scientiam's extensive expertise in digital biomarker development for chronic diseases and supported by Kyowa Kirin's resources, the collaboration aims to revolutionize the management of XLH by providing clinicians with new insights into the daily disease's impact on patients.

"XLH poses significant challenges for healthcare providers due to its diverse clinical manifestations and varying disease progression" said Emilie Bugeat-Toussaint, President of Kyowa Kirin France & BeNeLux. "By harnessing the power of digital biomarkers, we aim to enhance our understanding of XLH and ultimately improve patient outcomes."

Digital biomarkers enable high-frequency, longitudinal, and sensitive measurements from digital devices, such as smartphones, collected from patients' homes in real-life settings. This approach has the potential to provide clinicians with crucial information on XLH progression, facilitating personalized treatment strategies and enhancing patient care.

In the first phase, Ad Scientiam will collaborate with XLH experts and patient associations to identify digital biomarkers and outline product concepts for a software-based device. Conclusions are expected by the end of 2024, followed by software development and testing.

"Our partnership with Kyowa Kirin represents a significant step forward in our mission to address the unmet needs of XLH patients through cutting-edge digital solutions. These easy-to-use digital tools should help us better understand the real impact of the disease on patients' lives and demonstrate the benefits of novel therapies to keep the disease under control" said Matthieu Lamy, President at Ad Scientiam.

About Ad Scientiam

We strongly believe that continuously monitoring the progression of severe and disabling diseases in real-life is crucial for delivering better care.

To achieve this, we create and clinically validate digital biomarkers that make visible these previously undetectable changes. These biomarkers are developed using data collected through digital tools like smartphones and are transformed using proprietary algorithms.

We have gained the trust of hospital institutions such as the Paris Brain Institute (ICM) and pharmaceutical companies including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis. In 2019, we launched MSCopilot®, the first CE-marked software medical device for self-assessment of patients with multiple sclerosis. We are currently validating new devices in neuroscience, rare diseases, and mental disorders. Ad Scientiam is ISO 13485 certified.

Check our [LinkedIn](#) and [Facebook page](#) or visit adscientiam.com.

Press contact: info@adscientiam.com

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe.

You can learn more about the business of Kyowa Kirin at: <https://www.kyowakirin.com>